$SKYE
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Healthcare
Sector
Biotechnology
Industry
Punit S. Dhillon
CEO
16
Employees
$1.70
Current Price
$24.92M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 8 | $479,110.38 | 296,158 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 10 | $543,844.10 | 330,050 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 28 | $824,470.10 | 1,081,730 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 28 | $824,470.10 | 1,081,730 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
No earnings data in the last 3 months. Sign up free to see 12 months of history.